Publicaciones en las que colabora con Fe Tubau (20)

2023

  1. Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 36, Núm. 3, pp. 302-309

  2. Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysis

    The Lancet Regional Health - Europe, Vol. 34

  3. Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)

    eClinicalMedicine, Vol. 57

2021

  1. A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

    Infectious Diseases and Therapy, Vol. 10, Núm. 4, pp. 2677-2699

  2. Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018)

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 34, Núm. 3, pp. 228-237

  3. Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis

    Clinical Microbiology and Infection, Vol. 27, Núm. 11, pp. 1631-1637

2019

  1. Monitoring the antimicrobial susceptibility of gram-negative organisms involved in intraabdominal and urinary tract infections recovered during the smart study (Spain, 2016 and 2017)

    Revista Espanola de Quimioterapia, Vol. 32, Núm. 2, pp. 145-155

2018

  1. Antimicrobial susceptibility trends and evolution of isolates with extended spectrum β-lactamases among gram-negative organisms recovered during the SMART study in Spain (2011-2015)

    Revista Espanola de Quimioterapia, Vol. 31, Núm. 2, pp. 136-145

2017

  1. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

    The Lancet Infectious Diseases, Vol. 17, Núm. 7, pp. 726-734

  2. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study

    International Journal of Antimicrobial Agents, Vol. 50, Núm. 5, pp. 664-672

  3. MIC of amoxicillin/clavulanate according to CLSI and EUCAST: Discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 5, pp. 1478-1487

2016

  1. A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae

    Mayo Clinic Proceedings, Vol. 91, Núm. 10, pp. 1362-1371

  2. A multinational, preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing enterobacteriaceae

    Antimicrobial Agents and Chemotherapy, Vol. 60, Núm. 7, pp. 4159-4169

  3. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: A multinational pre-registered cohort study

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 6, pp. 1672-1680

2011

  1. Antimicrobial susceptibility of gram-negative organisms from intra abdominal infections and evolution of isolates with extended spectrum β-lactamases in the smart study in spain (2002-2010)

    Revista Espanola de Quimioterapia, Vol. 24, Núm. 4, pp. 223-232

2008

  1. Actividad comparativa de daptomicina frente a microorganismos grampositivos: Programa SENTRY España (2002-2006)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 26, Núm. 8, pp. 489-494

2007

  1. Evolution of the antimicrobial resistance of Pseudomonas aeruginosa in Spain: Second National Study (2003)

    Revista Espanola de Quimioterapia, Vol. 20, Núm. 2, pp. 222-229

  2. Recomendaciones para la selección de antimicrobianos en el estudio de la sensibilidad in vitro con sistemas automáticos y semiautomáticos

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 25, Núm. 6, pp. 394-400

2003

  1. Actividad in vitro comparativa de garenoxacino (BMS-284756). Programa SENTRY España (1999-2000)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 21, Núm. 8, pp. 404-409

1995

  1. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin

    European Journal of Clinical Microbiology & Infectious Diseases, Vol. 14, Núm. 3, pp. 244-252